OXiGENE, Inc. (Nasdaq: OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient has been enrolled ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE